

June 3, 2024

Krishna Vaddi
Chief Executive Officer
Prelude Therapeutics Incorporated
175 Innovation Boulevard
Wilmington, DE 19805

Therapeutics Incorporated

Statement on Form S-3

Re: Prelude

Registration

Filed May 30, 2024
File No. 333-279829

Dear Krishna Vaddi:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jason

Drory at 202-551-8342 with any questions.

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Bryan S. Keighery